Les psychédéliques peuvent-ils traiter l'anorexie et la dépression ? RESPADD, Actualités des Addictions, n°102, septembre 2019 Depuis son enfance, Rachael Petersen a vécu avec un sentiment de chagrin inexplicable qu'aucune pharmacothérapie ou psychothérapie n’a pu entièrement atténuer. Aussi, en 2017, elle s'est portée volontaire pour participer à un petit essai clinique à l'Université Johns Hopkins, qui testait la psilocybine, l'ingrédient actif des champignons hallucinogènes, pour le traitement de la dépression chronique. «J'étais tellement déprimée», a récemment déclaré Petersen, 29 ans. «J’ai eu l’impression que le monde m’avait abandonné, que j’avais perdu le droit d’exister sur cette planète. Vraiment, c’était comme si mes [...]
Lire la suiteHeavy cannabis use, dependence and the brain : a clinical perspective Emese Kroon, Lauren Kuhns, Eva Hoch & Janna Cousijn Addictions, 2019, 1-12. doi : 10.1111/add.14776 ABSTRACT Aims : To summarize and evaluate our knowledge of the relationship between heavy cannabis use, cannabis use disorder (CUD) and the brain. Methods : Narrative review of relevant literature identified through existing systematic reviews, meta-analyses and a PubMed search. Epidemiology, clinical representations, potential causal mechanisms, assessments, treatment and prognosis are discussed. Results : Although causality is unclear, heavy and dependent cannabis use is consistently associated with a high prevalence of comorbid psychiatric disorders and learning and memory impairments that seem [...]
Lire la suiteMarijuana Users May Be More Likely to Survive Acute Heart Failure Hospitalization Steve Stiles Medscape Medical News © 2019 , September 16, 2019 PHILADELPHIA — There's sunny news, potentially, for patients with heart failure who are keen on cannabis. Hospitalized patients with a primary diagnosis of acute heart failure (HF) who say they are marijuana users are more likely to survive to discharge than nonusers, and they stay fewer days at less cost to the hospital, an observational study suggests. It may be only patients with heart failure and reduced ejection fraction (HFrEF) who benefit, not those with heart failure and preserved ejection fraction (HFpEF), [...]
Lire la suiteCannabis et sécurité routière : en zone rurale, la répression plus dangereuse que la consommation ? Sur les routes de Lozère, une présomption d’innocence en ligne discontinue paru dans lundimatin#195, le 10 juin 2019 https://lundi.am/Cannabis-et-securite-routiere-en-zone-rurale-la-repression-plus-dangereuse-que-la-consommation Un lecteur de lundimatin nous a fait parvenir cette longue enquête à propos de la lutte contre la conduite après avoir fait usage de stupéfiants en Lozère. L’auteur est allé à la rencontre d’habitants et d’élus très critiques quant aux conséquences pratiques des tests salivaires. A cela s’ajoutent de nombreux témoignages de faux positifs et de conducteurs qui finissent sur le bord de la route : une punition vécue comme une injustice [...]
Lire la suiteLong-term Heavy Cannabis Use : implications for health education Niall COGGANS, Phil DALGARNO, Lindsay JOHNSON & David SHEWAN Drugs : education, prevention and policy, 2004, Vol. 11, No. 4, 299–313 ABSTRACT There is growing evidence that cannabis can have negative effects on health. While the ongoing debate about the nature and duration of these effects recognizes mild cognitive impairment, the evidence for irreversibility of cognitive impairment and causal links with psychiatric illness is not conclusive. There is undoubtedly potential for impairment of respiratory functioning, but that will depend on lifetime load and in most cases is confounded with tobacco smoking. There is a [...]
Lire la suiteThe association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study Nadav Shalita, Jürgen Rehmb, Shaul Lev-Ran Psychiatry Research, 2019, 278, 70–77 https://doi.org/10.1016/j.psychres.2019.05.041 A B S T R A C T Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals [...]
Lire la suiteAcute effects of delta-9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype Matthijs G. Bossong, Hendrika H. van Hell, Chris D. Schubart, Wesley van Saane, Tabitha A. Iseger, Gerry Jager, Matthias J.P. van Osch, J. Martijn Jansma, René S. Kahn, Marco P. Boks, Nick F. Ramsey European Neuropsychopharmacology, 2019, 13, 56, 1–11 https://doi.org/10.1016/j.euroneuro.2019.03.010 Abstract Cannabis produces a broad range of acute, dose-dependent psychotropic effects. Only a limited number of neuroimaging studies have mapped these effects by examining the impact of cannabis on resting state brain neurophysiology. Moreover, how genetic variation influences the acute effects of cannabis on resting state brain function [...]
Lire la suiteCannabis use, dependence and withdrawal in indigenous male inmates, Bernadette Rogerson et al., 2014
Cannabis use, dependence and withdrawal in indigenous male inmates Bernadette Rogerson, Susan P. Jacups, and Nerina Caltabiano Journal of Substance Use, 2014, 1–7 DOI: 10.3109/14659891.2014.950702 ISSN: 1465-9891 (print), 1475-9942 (electronic) Abstract Background : No studies have investigated cannabis withdrawal in indigenous or incarcerated populations, and there is currently no standard treatment for cannabis withdrawal in Australian prisons. Aims : This cross sectional survey examines cannabis use, dependence and involuntary (abrupt cessation) withdrawal in incarcerated indigenous males for the purpose of improving clinical management. Methods : 101 consenting inmates (18–40 years) from an Australian correction centre were interviewed. Demographic characteristics, lifetime cannabis use (LCU), severity of dependence, cannabis withdrawal [...]
Lire la suiteHeavy Cannabis Use, Dependence and the Brain: A Clinical Perspective KROON E., KUHNS L., HOCH E., COUSIJN J. Addictions, 2019 Aug 13. doi: 10.1111/add.14776. PMID: 31408248 Abstract AIMS : To summarize and evaluate our knowledge of the relationship between heavy cannabis use, Cannabis Use Disorder (CUD), and the brain. METHODS : Narrative review of relevant literature identified through existing systematic reviews, meta-analyses and a PubMed search. Epidemiology, clinical representations, potential causal mechanisms, assessments, treatment and prognosis are discussed. RESULTS : Although causality is unclear, heavy and dependent cannabis use is consistently associated with a high prevalence of comorbid psychiatric disorders and learning and memory impairments that seem [...]
Lire la suiteUse of Marijuana, Meth, Hallucinogens Up in New SAMHSA Survey Damian McNamara Medscape - Aug 22, 2019 Medscape Medical News © 2019 https://www.medscape.com/viewarticle/917131?nlid=131240_2052&src=WNL_mdplsnews_190823_mscpedit_psyc&uac=292598PZ&spon=12&impID=2070816&faf=1 Almost 1 million more Americans ages 12 or older reported using marijuana in their lifetime in 2018 than in 2017, according to new data from a national survey. The Substance Abuse and Mental Health Services Administration (SAMHSA) 2018 National Survey on Drug Use and Health Report notes that approximately 1.2 million more people reported use of hallucinogens, which include LSD, PCP, and Ecstasy, compared with 2017. In addition, about 170,000 more people used methamphetamine. Not all substance use increased year over year. For example, 187,000 fewer adolescent and adult Americans [...]
Lire la suite